Tian Zhang, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail DUMC 103861, Durham, NC 27710
Phone (919) 668-4667
Email address tian.zhang2@duke.edu

Education and Training

  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
  • Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
  • M.H.S., Duke University School of Medicine, 2019
  • M.D., Harvard Medical School, 2009

Grants

Publications

Schneider, A., T. Zhang, A. Kamal, K. Patel, E. P. Hamilton, and J. M. Peppercorn. “Pharmaceutical involvement in phase II breast cancer clinical trials.” In Journal of Clinical Oncology, 29:6104–6104. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.6104.

Full Text

Patel, K., A. Kamal, T. Zhang, A. Schneider, E. P. Hamilton, and J. M. Peppercorn. “The role of biologic therapy in phase II breast cancer clinical trials.” In Journal of Clinical Oncology, 29:e13048–e13048. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.e13048.

Full Text

Zhang, T., E. P. Hamilton, A. Schneider, K. Patel, A. Kamal, and J. M. Peppercorn. “Prevalence and impact of correlative science in breast cancer phase II trials.” In Journal of Clinical Oncology, 29:1046–1046. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.1046.

Full Text

Kamal, A., T. Zhang, A. Schneider, K. Patel, E. P. Hamilton, P. K. Marcom, and J. M. Peppercorn. “Outcomes in phase II trials of metastatic breast cancer: Where is the bar?” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 2590.

PMID
28022234
Scholars@Duke

Schneider, A., T. Zhang, A. Kamal, K. Patel, E. P. Hamilton, and J. M. Peppercorn. “Pharmaceutical involvement in phase II breast cancer clinical trials.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 6104.

PMID
28022553
Scholars@Duke

Zhang, T., E. P. Hamilton, A. Schneider, K. Patel, A. Kamal, and J. M. Peppercorn. “Prevalence and impact of correlative science in breast cancer phase II trials.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 1046.

PMID
28020693
Scholars@Duke

Patel, K., A. Kamal, T. Zhang, A. Schneider, E. P. Hamilton, and J. M. Peppercorn. “The role of biologic therapy in phase II breast cancer clinical trials.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): e13048.

PMID
28019865
Scholars@Duke

Brown, Landon C., Tian Zhang, and Daniel J. George. “The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials.” Cancer J 26, no. 5 (n.d.): 376–81. https://doi.org/10.1097/PPO.0000000000000469.

PMID
32947305
Full Text

Pages